Skip to content

Evaluation of clinical efficacy and safety of polymyxin and ceftazidime-avibactam based on time-event analysis

Evaluation of clinical efficacy and safety of polymyxin and ceftazidime-avibactam based on time-event analysis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300077215
Enrollment
Unknown
Registered
2023-11-01
Start date
2023-11-01
Completion date
Unknown
Last updated
2023-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gram-negative bacteria infection

Interventions

Patients with multidrug-resistant gram-negative bacteria treated with polymyxin or ceftazidime-avibatam:None

Sponsors

The Third Xiangya Hospital of Central South University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Pathogen culture results of carbapenem-resistant gram-negative bacterial infection; (2) A drug sensitivity test showing resistance to carbapenem antibiotics; (3) Sensitivity to polymyxin B, colistin sulfate, or ceftazidime-avibactam; (4) Duration of treatment > 72h.

Exclusion criteria

Exclusion criteria: (1) Patients who are allergic to therapeutic drugs; (2) non-intravenous or atomized administration; (3) non-hospitalized patients; (4) Patients for whom the available data are insufficient to judge the clinical outcome or renal toxicity; (5) Combined with malignant tumors or multiple organ failure.

Design outcomes

Primary

MeasureTime frame
Plasma concentration;

Secondary

MeasureTime frame
C-reactive protein;Procalcitonin;White blood cell;

Countries

China

Contacts

Public ContactPei Qi

The Third Xiangya Hospital of Central South University

peiqi1028@126.com+86 131 7041 9804

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026